

Table of contents

| | |
|---|-----|
| <i>Rector Magnificus Per Eriksson</i> : Falck - Hillarp: an example for the future | 3 |
| <i>Introduction</i> . The Falck - Hillarp method: 50 years in perspective | 5 |
| <i>Anders Björklund and Olle Lindvall</i> : Cell transplantation for Parkinson's Disease in Lund. Some personal recollections | 9 |
| <i>Angela Cenci-Nilsson</i> : Landmarks in the development of pharmacotherapies for Parkinson's disease | 43 |
| <i>Torgny Svensson and Monica M. Marcus</i> : Treatment of schizophrenia. Significance of presynaptic α_2 adrenoceptors. | 53 |
| <i>Elias Eriksson</i> : Serotonin as a target for antidepressant and anxiety-reducing drugs | 63 |
| <i>Ingrid Carlberg</i> : "Lyckopillrens" segertåg. (Summary in English: "Novel antidepressants: A success story?" by Rolf Håkanson) | 79 |
| <i>Håkan Ahlman</i> : From enterochromaffin cell to midgut carcinoid tumour | 91 |
| <i>Enar Carlsson</i> : Losec, a Swedish success story | 105 |
| <i>Jens J. Holst</i> : From gastro-entero-pancreatic cells to treatment of diabetes and obesity | 119 |
| <i>Christian Broberger</i> : Brain hormones (Presentation reporter: Berndt Ehinger) | 131 |
| <i>Johan Franck</i> : Substance use disorders are brain disorders | 139 |
| <i>Rolf Håkanson</i> : Summary of panel discussion on what characterizes creative environments | 149 |
| Acknowledgements | 160 |